Получение и изучение свойств противоопухолевого лекарственного средства на основе липидного производного сарколизина
##plugins.themes.bootstrap3.article.main##
Аннотация
Оптимизированы условия получения лекарственного средства на основе липидного производного сарколизина, встроенного в фосфолипидные наночастицы. Препарат представляет собой ультратонкую эмульсию со светопропусканием выше 80% и размером частиц не более 50 нм. При этом 99% липидного производного сарколизина встроено в фосфолипидные наночастицы. Сохранение агрегационной устойчивости в водной среде наблюдалось как минимум в течение 2-х суток. Эксперименты in vitro показали, что сарколизин, введенный в составе фосфолипидных наночастиц, распределяется по липопротеинам и белковым компонентам плазмы крови. При этом содержание сарколизина во всех фракциях, участвующих в транспорте биологически активных веществ в организме, значительно выше при введении в виде пролекарства (липидного производного сарколизина) в составе фосфолипидных наночастиц, чем при введении сарколизина в инкубационную среду в свободном виде (т.е. фармакологической субстанции). Превращение пролекарства в лекарство сарколизин происходит в клетках форменных элементов.
##plugins.themes.bootstrap3.article.details##
Как цитировать
Терешкина Y., Санжаков M., Кострюкова L., Короткевич E., Чистов A., Тихонова E., Прозоровский V., & Ипатова O. (2019). Получение и изучение свойств противоопухолевого лекарственного средства на основе липидного производного сарколизина. Biomedical Chemistry: Research and Methods, 2(3), e00098. https://doi.org/10.18097/BMCRM00098
Выпуск
Раздел
ЭКСПЕРИМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯ
Библиографические ссылки
- Xiaomei, M., Herbert, Y. (2006) Global Burden of Cancer. Yale J. Biol. Med, 79 (3-4), 85–94.
- Karpunin, V.O., Klenov, G.I., Khoroshkov, B. C. (2008) Russia's first specialized clinical center for proton radiation therapy. Clinical Medicine Almanac, 17 (1), 316-319.
- Thomas, D, Radhakrishnan, P. (2019) Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis. Mol Cancer, 18 (1), 14. DOI
- Warwi, G. P. (1963) The Mechanism of Action of Alkylating Agents. Cancer Research, 23, 1315-1333.
- Baryshnikov, A.Yu., Zimakova, N.A., Kikot, B.S. (2001) Chemical and pharmaceutical research of a new drug form of sarcolysine. Chemical-pharmaceutical journal, 12, 42-47.
- Zhukova, O.V., Bulgakova, S.A., Khokhlova, T.L. (2012) Some approaches to the creation of pharmacologically active polymer derivatives of drugs with antitumor activity. Pharmateca. Oncology, 18 (251), 14-19.
- Bogomilova, A., Höhn, M., Günther, M., Herrmann, A., Troev, K., Wagner, E., Schreiner, L. (2013) A polyphosphoester conjugate of melphalan as antitumoral agent. Eur. J. Pharm. Sci., 50(3-4), 410-419.
- Baryshnikov, A. Yu. (2012) Nanostructured liposomal systems as a means of delivery of antitumor drugs. Bulletin of the Russian Academy of Medical Sciences, 67 (3), 23-31.
- Panahi, Y., Farshbaf, M., Mohammadhosseini, M., Mirahadi, M., Khalilov, R., Saghfi, S., Akbarzadeh, A. (2017) Recent advances on liposomal nanoparticles: synthesis, characterization and biomedical applications. Artificial Cells, Nanomedicine, and Biotechnology, 45 (4), 788-799. DOI
- Hrkach, J.., Von Hoff, D., Mukkaram, A. M., Andrianova, E., Auer, J., Campbell, T., De Witt, D., Figa, M., Figueiredo, M., Horhota, A., Low, S., McDonnell, K., Peeke, E., Retnarajan, B., Sabnis, A., Schnipper, E., Song, J.J., Song, Y.H., Summa, J., Tompsett, D., Troiano, G., Van Geen Hoven, T., Wright, J., LoRusso, P., Kantoff, P.W., Bander, N.H., Sweeney, C., Farokhzad, O.C., Langer, R., Zale, S. (2012) Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Transl. Med., 4, 128-139. DOI
- Kolishetti, N., Dhar, S., Valencia, P.M., Lin, L.Q., Karnik, R., Lippard, S.J., Langer, R., Farokhzad, O.C. (2010) Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc. Natl. Acad. Sci. U. S. A., 107, 17939-17944. DOI
- Chang, H.I., Yeh, M.K. (2012) Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int. J. Nanomedicine, 7, 49-60. DOI
- Hamaguchi, T.., Kato, K., Yasui, H., Morizane, C., Ikeda, M., Ueno, H., Muro, K., Yamada, Y., Okusaka, T., Shirao, K., Shimada, Y., Nakahama, H., Matsumura, Y. (2007) A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation. Br. J. Cancer, 97, 170-176. DOI
- Egusquiaguirre, S.P., Igartua, M., Hernández, R.M. Pedraz, J.L . (2012) Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research. Clin. Transl. Oncol., 14 (2), 83-93. DOI: 10.1007/s12094-012-0766-6
- Svistelnik, A.V., Khanin, A. L. (2014) Liposomal drugs: opportunities and prospects. Medicine in Kuzbass, 2, 7-16.
- Bielawski, K., Bielawska, A. (2008) Small-molecule based delivery systems for alkylating antineoplastic compounds. ChemMedChem, 3(4), 536-542. DOI
- Vodovozova, E.L., Gaenko, G.P., Bobrikova, E.S., Pazynina, G.V., Molotkovsky, Yul.G. (2007) Diglyceride derivative of methotrexate: synthesis and cytotoxic activity in targeted liposomes. Chemical-pharmaceutical journal, 41(6), 10-14. DOI
- Zanette, M., Marcomini, A., Marchiori, E., Samperi, R. (1996) High-performance liquid chromatographic-fluorescence determination of aliphatic alcohol polyethoxylates and polye(thyleneglycol)s in aqueous samples. Journal of Chromatography A., 756 (1–2), 159-174. DOI
- Shironin, A.V., Ipatova, O.M., Medvedeva, N.V., Prozorovskiy, V.N., Tikhonova, E.G., Zakharova, T.S., Sanzhakov, M.A., Torhowskaya, T.I. (2011) Increased bioavailability and anti-inflammatory efficacy of indomethacin when embedded in phospholipid nanoparticles. Biomedical chemistry, 57(6), 671-676. DOI
- Sanzhakov, M.A., Prozorovsky, V.N., Ipatova, O.M., Tikhonova, E.G., Medvedeva, N.V., Torkhovskaya, T.I. (2013) Transport system based on phospholipid nanoparticles for rimfapicin. Biomedical Chemistry, 59 (8), 585-590.
- Guseva, D.A., Khudoklinova, Yu.Yu., Medvedeva, N.V., Baranova, V.S., Zakharova, T.S., Artyushkova, E.B., Torkhovskaya, T.I., Ipatova, O.M. (2015) The effect of incorporation of resveratrol and dihydroquercetin into phospholipid nanoparticles on their bioavailability and specific activity. Biomedical Chemistry, 61 (5), 598-605. 10.18097/PBMC20156105598 ' target='_blank' > DOI
- Medvedeva, N.V., Torkhovskaya, T.I., Kostryukova, L.V., Zakharova, T.S., Kudinov, V.A., Kasatkina, E.O., Prozorovsky, V.N., Ipatova, O.M. (2017) The effect of the incorporation of doxorubicin into phospholipid nanoparticles on tumor accumulation and specific activity. Biomedical Chemistry, 63 (1), 56-61. DOI
- Sanzhakov, M.A., Ipatova, O.M., Torkhovskaya, T.I., Tikhonova, E.G., Medvedeva, N.V., Zakharova, T.S., Prozorovsky, V.N. (2018) Increasing the anti-tuberculosis effect of rifampicin upon incorporation into phospholipid nanoparticles with sodium oleate. Biomedical Chemistry, 64 (6), 505-510. DOI
- Medvedeva, N.V. Prozorovskiy, V.N., Ignatov, D.V., Druzhilovskaya, O.S., Kudinov, V.A., Kasatkina, E.A., Tikhonova, E.G., Ipatova, O.M. (2015) Drugs and transport nanosystems based on plant phospholipids. Biomedical chemistry, 61 (2), 219-230. DOI
- The State Pharmacopoeia of Russian Federation. 12 th ed. (2007) Moscow: Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» of the Ministry of Health of the Russian Federation.
- GOST R 56702-2015. (2016) Medicines for medical applications. Nonclinical toxicology and pharmacokinetic studies of safety. Moscow: Standartinform.
- Masquelier, M., Vitols, S., Peterson, C. (1986) Low-density lipoprotein as a carrier of antitumoral drugs: in vivo fate of drug-human low-density lipoprotein complexes in mice. Cancer Res., 46 (8), 3842-3847.
- Dutta, R.C. (2007) Drug carriers in pharmaceutical design: promises and progress. Curr. Pharm. Res., 13 (7), 761-769.
- Torhovskaya, T.I., Ipatova, O.M., Medvedeva, N.V., Ivanov, V.S., Ivanova, L.I. (2010) Blood plasma lipoproteins as carriers of drugs. Effect of phospholipid dosage forms. Bulletin of the Russian Academy of medical Sciences, 5, 42-50.
- Shironin, A.V., Ipatova, O.M., Medvedeva, N.V., Prozorovskiy, V.N., Tikhonova, E.G., Torhovskaya, T.I. (2012) Injectable form of indomethacin in phospholipid nanoparticles: Association with low density lipoproteins and anti-inflammatory action. Efferent and physico-chemical medicine, 1, 21-24.
- Zykova, M.A., Ipatova, O.M., Prozorovskiy, V.N., Medvedeva, N.V. Voskresenskaya, A.A., Zakharova, T.S., Torhowskaya, T.I. (2011) Changes in the distribution of doxorubicin in blood and plasma when it is included in the phospholipid nanocomposition. Biomedical chemistry, 57 (2), 174-179. DOI
- Wasan, K.M., Ramaswamy, M., Cassidy, S.M., Kazemi, M., Strobel, F.W., Thies, R.L. (1997) Physical characteristics and lipoprotein distribution of liposomal nystatin in human plasma. Antimicrob. Agents Chemother, 41 (9), 1871-1875.
- Ahmed, A.E., Hsu, T.F., El-Azhary, R.A., Moawad, H., Costanzi, J. (1982) Macromolecular interactions of [14c-ring]melphalan in blood. Biochem. Pharmacology, 31 (8), 1615-1619.